GSKure
Therapeutic Target for Treating Neurogenetic Disorders
StartupGSKure is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2016. Therapeutic Target for Treating Neurogenetic Disorders . GSKure was founded by Hagit Eldar- Finkelman, Ph.D.. The company has 1-10 employees. Core technologies: Biologicals, Molecules.
The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StagePre-Funding
- ProductR&D
- ModelB2B
- Employees1-10
- HQTel Aviv-Yafo
- DistrictCenter District
- Last RoundUndisclosed
Hagit Eldar- Finkelman, Ph.D.Founder & CEO
1 article covered by sources including www.israel21c.org.
What does GSKure do?
GSKure is an IP-based company that owns innovative proprietary GSK-3 peptide inhibitor drug candidates. The company's Kure products are based on a novel design of compounds that target a unique region at the GSK-3 protein surface termed the substrate binding site. The substrate-competitive inhibitors (SCIs) show improved selectivity and low toxicity compared to traditional ATP-competitive inhibitors. GSKures novel SCI strategy for drug design offers significant advantages for clinical practice. Professor Hagit Eldar-Finkelman of Tel Aviv University conducted pioneering studies in developing GSK-3 inhibitors and their therapeutic use in treating human disease.
Who founded GSKure?
GSKure was founded in 2016 by Hagit Eldar- Finkelman, Ph.D. (Founder & CEO).
What sector is GSKure in?
GSKure operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology, Healthcare, Patients.
Where is GSKure located?
GSKure is based in Tel Aviv-Yafo, Israel, Center District.